Palvella Therapeutics, Inc.

PVLA

Healthcare|Biotechnology|US

$175.92

+19.07 (+12.16%)

DCF Value

$4.71

Tangible Book / Share

$13.62

Cash / Share

$16.29

Next Earnings Report

Mar 30, 2027

EPS est. -$1.81 · Revenue est. $16.7K

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Feb 26, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (1)

Aug 2027

Est. completion

P2Angiokeratomas

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

NCT07552077n=15

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Jan 2026

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

NCT06239480

Nov 2025

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

NCT06653842

Recent Press Releases

Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nov 5, 2026 · GlobeNewsWire

Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference

Nov 3, 2026 · GlobeNewsWire

Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026

Oct 29, 2026 · GlobeNewsWire

Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set

Oct 28, 2026 · GlobeNewsWire

Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference

Oct 15, 2026 · GlobeNewsWire

Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

Oct 13, 2026 · GlobeNewsWire

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Sep 28, 2026 · GlobeNewsWire

Palvella Therapeutics Appoints James R. Treat, M.D.

Sep 9, 2026 · GlobeNewsWire

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Sep 2, 2026 · GlobeNewsWire

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Aug 31, 2026 · GlobeNewsWire

SEC Filings (84)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Nov 5, 2026	10-Q	Quarterly report	Document Index
Nov 5, 2026	8-K	Material event	Document Index
Oct 28, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Oct 28, 2026	8-K	Material event	Document Index
Aug 14, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Aug 14, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Aug 10, 2026	SC 13G	Passive 5%+ stake	Document Index
Aug 4, 2026	S-8	Employee stock plan	Document Index
Aug 4, 2026	10-Q	Quarterly report	Document Index
Aug 4, 2026	8-K	Material event	Document Index
Aug 3, 2026	SC 13G	Passive 5%+ stake	Document Index
Jul 29, 2026	SC 13G	Passive 5%+ stake	Document Index
Jul 14, 2026	8-K	Material event	Document Index
Jun 30, 2026	8-K	Material event	Document Index
Jun 16, 2026	8-K	Material event	Document Index
May 20, 2026	8-K	Material event	Document Index
May 15, 2026	8-K	Material event	Document Index
May 13, 2026	8-K	Material event	Document Index
May 7, 2026	8-K	Material event	Document Index
May 7, 2026	10-Q	Quarterly report	Document Index
Apr 30, 2026	ARS	Annual report to holders	Document Index
Apr 30, 2026	DEFA14A	Proxy / shareholder vote	Document Index
Apr 30, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Apr 13, 2026	8-K	Material event	Document Index
Apr 7, 2026	8-K	Material event	Document Index
Mar 31, 2026	10-K	Annual report	Document Index
Mar 31, 2026	8-K	Material event	Document Index
Feb 26, 2026	8-K	Material event	Document Index
Feb 26, 2026	424B5	Offering prospectus	Document Index
Feb 24, 2026	424B5	Offering prospectus	Document Index
Feb 24, 2026	8-K	Material event	Document Index
Feb 24, 2026	8-K	Material event	Document Index
Feb 24, 2026	8-K	Material event	Document Index
Feb 17, 2026	SC 13G	Passive 5%+ stake	Document Index
Feb 17, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Feb 13, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Jan 29, 2026	EFFECT		Document Index
Jan 29, 2026	8-K	Material event	Document Index
Jan 12, 2026	8-K	Material event	Document Index
Jan 2, 2026	S-3	Shelf registration	Document Index